Breaking News

Altimmune Adds Lonza as Mfg. Partner for Supply of AdCOVID

Single-dose intranasal vaccine for COVID-19 designed to generate a broad immune response with nasal mucosal immunity to prevent infection and transmission.

By: Contract Pharma

Contract Pharma Staff

Altimmune, Inc., a clinical-stage biopharmaceutical company, entered into an agreement with Lonza for the manufacture of AdCOVID, Altimmune’s next-gen, a single-dose intranasal vaccine candidate for COVID-19. Lonza is a leading global biopharmaceutical manufacturing company with facilities in Europe, North America, and South Asia. AdCOVID is a single-dose COVID-19 vaccine candidate that has the potential to be conveniently administered via an intranasal spray. In addition to activating syste...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters